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Abstract
Backgound: Multiple Sclerosis has two clinical phases reflecting distinct but inter-related pathological processes:
focal inflammation drives the relapse-remitting stage and neurodegeneration represents the principal substrate of
secondary progression. In contrast to the increasing number of effective anti-inflammatory disease modifying
treatments for relapse-remitting disease, the absence of therapies for progressive disease represents a major
unmet clinical need. This raises the unanswered question of whether elimination of clinical relapses will prevent
subsequent progression and if so how early in the disease course should treatment be initiated. Experimental
autoimmune encephalomyelitis in the Biozzi ABH mouse recapitulates the clinical and pathological features of
multiple sclerosis including relapse-remitting episodes with inflammatory mediated demyelination and progressive
disability with neurodegeneration. To address the relationship between inflammation and neurodegeneration we
used an auto-immune tolerance strategy to eliminate clinical relapses in EAE in a manner analogous to the clinical
effect of disease modifying treatments.
Results: By arresting clinical relapses in EAE at two distinct stages, early and late disease, we demonstrate that
halting immune driven demyelination even after the first major clinical event is insufficient to prevent long-term
neurodegeneration and associated gliosis. Nonetheless, early intervention is partially neuroprotective, whereas
later interventions are not. Furthermore early tolerisation is also associated with increased remyelination.
Conclusions: These findings are consistent with both a partial uncoupling of inflammation and neurodegeneration
and that the regenerative response of remyelination is negatively correlated with inflammation. These findings
strongly support the need for early combinatorial treatment of immunomodulatory therapies and neuroprotective
treatments to prevent long-term neurodegeneration in multiple sclerosis.
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Background
Multiple sclerosis (MS) is the most common cause of
acquired neurological disability in young adults [1]. In the
majority of patients multiple sclerosis has two clinical
phases reflecting distinct but inter-related pathological
processes: focal inflammation drives activity during the
relapse-remitting (RR) stage and neuroaxonal degener-
ation represents the principal substrate of secondary
progression (SP), a stage that has few if any relapses.
Despite important and continuing advances in treatment
of early RR disease with disease modifying treatments
(DMTs) that target the inflammatory response, the absence
of therapies for progressive disease represents a major
unmet clinical need for patients.
The inability of immunosuppressive therapies to influ-
ence progressive disease despite suppressing radiological
and clinical measures of inflammation highlights a major
unresolved question in disease evolution as to the precise
relationship between inflammation and neurodegene-
ration [2]. Indirect observations such as neuronal injury in
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normal appearing white matter and epidemiological
findings that time to disease progression is age dependent,
but independent of number of relapses, suggests that
neurodegeneration is at least in part independent of
immune-driven inflammation [3,4]. An equally plausible
case can be made for interdependency whereby inflamma-
tion initiates a cascade of events that is necessary for sub-
sequent neurodegeneration [5-7]. In addition, recognition
from experimental models that inflammation can be
beneficial for remyelination, that can be neuroprotective,
adds a further impetus to a better understanding of the
relationship between inflammation and neurodegene-
ration [8-10].
Chronic relapsing experimental autoimmune enceph-
alomyelitis (crEAE) induced in the Biozzi ABH mouse
using spinal cord homogenate recapitulates many of the
clinical and pathological features of MS including RR
episodes and secondary progression, which is associated
with accumulating disability along with inflammatory
mediated demyelination, neurodegeneration and remye-
lination [11-16]. Furthermore the ability to eliminate
clinical relapses in EAE, using auto-immune tolerance
(analogous to the clinical effect of newer disease modify-
ing treatments for multiple sclerosis) achieved with tran-
sient antibody mediated T cell depletion and intravenous
myelin antigen administration allows evaluation of the
contribution of inflammation to neurodegeneration and
regeneration to be studied [17,18]. The emergence of
increasingly powerful and effective anti-inflammatory
DMTs used in RR disease raises the questions of
whether these treatments will prevent progression, does
the timing of intervention matter and what is the
pathological correlate of any putative effect? Definitive
evaluation requires long-term human studies with follow
up over many years in different temporal cohorts and is
currently unrealistic.
The effectiveness of tolerisation to eliminate further
clinical relapses in EAE in Biozzi ABH mice has
previously been shown [17-19]. We sought to extend the
capability of the Biozzi-EAE experimental system to
pathologically dissect the consequences of tolerisation
with respect to timing of intervention - using tolerisa-
tion at two clinical stages chosen to reflect early and late
RR disease - and the systematic quantification of axonal
and neuronal loss, as well as myelination status.
We show that although early tolerisation is partially
neuroprotective, unlike later intervention, there is an
on-going neuronal and axonal degeneration even in the
absence of any further clinical relapses. Furthermore
there is an association between early tolerisation and
increased remyelination. These findings are consistent
with both a partial uncoupling of inflammation and
CNS neurodegeneration and that the regenerative re-
sponse of remyelination is negatively correlated with
this inflammation. These findings strongly support the
need not only for early treatment of patients with MS
(that requires further advances in identifying symptoms)
but that early combinatorial treatment of immunomodula-
tory therapies alongside neuroprotective treatments might
be key to prevent long-term neurodegeneration in MS.
Methods
Animals and surgery
All procedures were performed in compliance with na-
tional and institutional guidelines (UK Animals (Scientific
Procedures) Act 1986 and the University of London
Animal Care Committees). These studies were undertaken
to conform with the ARRIVE guidelines as described
previously [20].
Induction of EAE and tolerisation
Female 10–12 week specific pathogen free Biozzi ABH
mice, stock bred at Queen Mary University of London,
were group housed (n = 8-10) in environmentally-enriched
cages in humidity and temperature controlled rooms
and were provided access to food and water ad libitum.
Mice were inoculated as previously described [12,20].
Briefly, mice were injected subcutaneously with 1 mg
spinal cord homogenate emulsified in Freunds adjuvant
supplemented with 60 mg Mycobacterium tuberculosis
H37Ra and M. butyricum in both hind flanks at day 0
and day 7. Mice were monitored and scored daily as
follows: 0 = normal, 1 = limp tail, 2 = impaired righting
reflex, 3 = hind-limb paresis; 4 = complete hind-limb
paralysis and 5 =moribund/death. Signs of reduced se-
verity were scored at 0.5 less than the indicated grade
[12]. Immune tolerance to inhibit further relapsing auto-
immunity was induced by intraperitoneal injection of
250 μg YTS191, CD4 depleting monoclonal antibody
followed one week later by the intravenous injection
of 2 × 107 splenocytes chemically coupled to spinal
cord homogenate (Ag-Splenocytes) as described pre-
viously [12,17]. All experiments were performed over
3 separate cohorts of mice, each cohort being used to gen-
erate different groups or part of the groups (including,
normal, day 29, 58 or 105 EAE progression or early and
late tolerised).
Immunohistochemistry
Tissue was collected at 3 timepoints as follows - from
control EAE, non-tolerised animals at the two time
points, day 29 and 58 post EAE induction, as well as at
the chronic timepoint of 105 days. Tissue from mice
tolerised early (day 29) and late (day 58) was collected at
105 days, as well as tissue from age-matched naive
Biozzi ABH mice (i.e. 6 month old mice) – See Figure 1a.
All animals were terminally anaesthetised (a lethal dose
of sodium pentobarbitone, Euthatal, at 0.3 ml/100 g
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bodyweight i.p.) and rapidly perfused with cold phos-
phate buffer saline (PBS) prewash followed by cold 4%
paraformaldehyde in PBS. The spinal cord was dissected
as individual segments and postfixed in either 4% parafor-
maldehyde overnight before being cryoprotected in 25%
sucrose or postfixed in 4% gluteraldehyde. Cryoprotected
spinal cords were sectioned para-sagitally (16 μm) with a
cryostat, thaw-mounted onto superfrost-plus glass slides
(VWR international, UK), and stored at -80°C. Sections for
immunofluoresence were processed as previously descri-
bed [21,22]. Briefly, slides were defrosted and air-dried for
several hours before being washed in PBS and then
Figure 1 Timecourse of disease progression and effectiveness of tolerisation on clinical relapses, disease progression and IgG
immunoreactivity. Timeline illustrating experimental groupings following EAE induction (29, 58 and 105 days) and timepoints when tolerisation
was instigated and collection of tissue occurred (a). Behavioural data (b) showing disease progression of EAE in Biozzi ABH mice (black line)
compared to early (red, tolerised day 29) and late (green, tolerised day 58) tolerised mice, where 0 is normal upto 5, moribund. Representative
IgG images from the cervical spinal (c) cord showing normal (N = 3) compared to EAE disease progression at day 29 (N = 5), 58 (N = 5), 105
(N = 4), early (N = 4) and late tolerisation (N = 6). Quantification of IgG immunoreactivity (d) showing there are clear, significant increases in
intensity (over the first 200 μm from the surface of the dorsal funiculus down) At day 29, 58 and 105 (black asterisk, d). Following early and late
tolerisation there is a significant reduction compared to day 105-crEAE (red and green lines/asterisk respectively d, asterisk = P < 0.01, one-way
ANOVA). Scale bar = 200 μm for all images.
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blocked for one hour using 3% normal goat serum (NGS)
or normal horse serum (NHS) depending on secondary
antibodies to be used, in a 0.2% Triton-X100 detergent
solution of phosphate buffer (TX-PBS). Primary anti-
bodies were applied overnight in TX-PBS containing
1% normal serum, appropriate for the secondary anti-
body. Primary antibodies used were polyclonal goat-ChAT
(1:200, Chemicon UK), polyclonal rabbit-calcitonin gene-
related peptide (CGRP) (Sigma, Poole UK 1:4000), mono-
clonal glial fibrillary acidic protein (GFAP) clone GA5-Cy3
(1:500, Sigma, Poole, UK), polyclonal chicken anti-MAP2
(AbCam, Cambridge UK, 1:1000), monoclonal mouse-
NeuN-biotinylated (1:400, Millipore Bioscience Research
Reagents UK) and goat polyclonal-IBA1 (1:150, AbCam,
UK). After several washes in PBS, secondary antibodies
were added for 2 hours in TX-PBS containing 1% NGS or
NDS and bis-benzamide (Sigma, 1:4000). Secondary anti-
bodies used were Alexa 488, 555 and/or 647 (Molecular
Probes/Invitrogen, UK, 1:1000). Slides were washed in
PBS followed by a final wash in Tris buffered non-saline
(TNS) before being mounted using fluorosave reagent
(Calbiochem, Nottingham, UK).
Preparation of semi-thin resin sections
Spinal cord sections for resin embedding were taken
from the PFA fixed animals and immediately post-fixed
using 4% gluteraldehyde in PBS, before being transferred
to PBS prior to embedding. Processing was done as pre-
viously described [22]. Briefly sections were washed
again in PBS, before being placed in 2% osmium tetraox-
ide (TAAB Labs, Aldermaston, UK) overnight at 4°C.
The following day the tissue was dehydrated in a graded
series of ethanol washes, followed by propylene oxide
and then with propylene oxide/resin mix for 3 hours.
Following two immersions in 100% resin (minimum of
6 hours each), sections were embedded individually in
beam capsules and hardened at 60°C over 24 hours.
Semithin sections were cut using 6 mm glass knives
on a Reichert-Jung Ultracut microtome. These were
placed on Polysine slides (VWR international, UK) in a
droplet of distilled water and flattened by placing and
manually rotating the slide on a heat plate. Once sec-
tions were dry, the slide was flooded with toluidine blue
(5% in a Borax solution) and heated again until vapours
evolved. The stain was removed in a stream of hot
water and sections dried on a hot plate. Finally slides
were cleared in xylene, before being mounted using
DPX solution.
Preparation of fresh-frozen sections
Tissue was collected at 3 timepoints as follows - from
control EAE, non-tolerised animals at day 29 post EAE
induction, as well as at the chronic timepoint of 105 days.
Tissue from mice tolerised early (day 29) and late (day 58)
was collected at 105 days, as well as tissue from age-
matched naive Biozzi ABH mice (i.e. 6 month old
mice) – See Figure 1a. All animals were euthanized
using increasing levels of CO2 and rapidly perfused
with cold phosphate buffer saline (PBS) prewash and
the spinal cord was removed before being snap frozen.
Spinal cords were sectioned para-sagitally (16 μm) with a
cryostat, thaw-mounted onto superfrost-plus glass slides
(VWR international, UK), and stored at -80°C. Sections
for CD4 immunofluoresence were defrosted and air-dried
overnight before being fixed in ice-cold acetone for
5 minutes and then air-dried for a further hour. Block
was applied (5% NGS in PBS) for one hour before
monoclonal anti-CD4-directly conjugated to Alexa-488
(1:100, eBioscience, UK) was added with 3% NGS in PBS
for 2 hours. After several washes in PBS followed by
a final wash in Tris buffered non-saline (TNS), slides
were mounted using fluorosave reagent (Calbiochem,
Nottingham, UK).
Analysis
Images were captured using a Zeiss Axiovision micro-
scope and axiovision 4.8 software via a digital camera or a
Zeiss LSMZ10 Confocal microscope using Zen 2009 soft-
ware. SigmaScan Pro 5.0 (SPSS, Chicago, IL) was used for
subsequent quantitative measurements. Immunopositive
cell density measurements were made on thresholded
overlays of transverse spinal cord segment images (in
which all pixels overlying immunopositive cells had a
greyscale value of 68, and all other pixels had a value of 0),
such that average intensity could be converted to density
measurements by dividing the output by 68 leading to a
scale of 0 (minimum) to 1 (maximum possible reading)
being generated. This analysis used an automated thresh-
olding procedure [13,22,23]. GFAP and IBA1 densitomet-
ric measurements were made on the resulting combined
thresholded overlays as a function of distance from the
dorsal surface through the dorsal funiculus. This method
of quantification measures the density of immunopositive
objects independent of their individual intensities. Follow-
ing this the data was averaged and presented over the set
depth of 100 μm (GFAP) or 300 μm (IBA1) from the
surface of the dorsal funiculus.
CGRP analysis was performed through the dorsal
horn, on thresholded images as described above and
identically to previous methodology [13] except instead
of presenting analysis as a function of intensity over
depth – data was averaged over 50 μm. NeuN counts
were performed in the Lateral Spinal Nucleus (LSN) as
defined by overlaying CGRP-MAP2 and NeuN images,
such that the LSN is MAP2 positive, but no CGRP
positive fibres are present within the LSN [24] and only
NeuN positive nuclei that fell within this MAP2 positive
area were counted in a total of six areas per animal.
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Secondary mouse IgG (Alexa 488) alone images were
all generated and handled identically to eliminate
personal bias and errors. Once images were captured
the raw tiff files were opened in SigmaScan pro 5.0
and the total pixel intensity under a defined area
was calculated. A minimum of 3 to a maximum of 6
sections were analysed per animal and 3 measurements
were made on each image such that the whole dorsal
funiculus, the gracillus or cuneatus alone were measured
and quantified.
Semithin sections (n = 5, a minimum of 3 sections per
animal) were analysed by counting toluidine blue stained
normal myelin, preserved demyelinated axons or thinly
myelinated axons (denoting potential remyelination) that
dissected a counting line (with a total of 5 counts per
section taken) at specified depths through the dorsal
funiculus. All counts were performed blinded and data
plotted as a percentage of total axons remaining in the
cervical spinal cord segment of crEAE mice compared
to normal, healthy controls. In addition total area of
spinal cord segments was also quantified (n = 4 or 5, a
minimum of 3 sections per animal) at all timepoints
to examine any potential oedema within the spinal
cord tissue.
Graphs were generated using graphing software (Sigma
Plot 11) and only statistically significant results are dis-
cussed. Statistical tests were performed using SigmaStat
and significance only assumed in ANOVA tests using the
more stringent Tukey post-hoc Test and a threshold of
p = <0.01.
Results
To fully characterise and control our experiment it was
necessary to take multiple animals at key timepoints in
disease and treatment (Figure 1a) as follows:
1. Normal control mice
2. EAE disease – day 29, 58 and 105
3. Early-tolerised mice (tolerised at day 29) tissue
collected at 105 days
4. Late-tolerised mice (tolerised at day 58) tissue
collected at 105 days
During crEAE in Biozzi ABH mice, lesions occur
along virtually the entire neuroaxis during active
paralytic disease and occurs consistently in the cer-
vical spinal cord regions examined (4,18). However,
the amount of immune infiltration is dramatically lost
as animals remit (4,12), such that spinal cord can
appears relatively normal (4), but residual lesions ac-
cumulate with time (4,12). Analysis was undertaken
in areas where lesions would have been present, as
clearly shown in our previous detailed characterisation
studies (18,22).
Immunological tolerance prevents further relapses in
chronic-relapsing EAE
In order to explore the pathological consequences of
differential timing of immunosuppresion, immunological
tolerance was induced at early (day 29) and late (day 58)
time points. These stages of EAE, chosen to mimic
common clinical scenarios, represent the recovery stage
after the first attack (day 29) and early progressive disease
phase with super-imposed relapses (day 58; Figure 1a).
Early and late immunological tolerance treatment pre-
vented further relapses, characterised by discrete weight
loss and a noticeable increase in neurological score [20].
This halted evolution of clinical deficits, as assessed using
the clinical score, from time of treatment initiation,
consistent with previous findings, Figure 1b [17]. Any var-
iations in daily clinical score were minor and reflected
subtle scoring differences of the subjective scoring system
(Figure 1b). Although early treatment results in negligible,
long-term residual clinical deficit (Figure 1b, red line), the
late treatment group remained significantly disabled with
persistent limb paresis (Figure 1b, green line) with no
evidence of reversal of disability, again in agreement with
previous results [17,19]. Having established a reproducible
model in which inflammatory activity manifesting clinic-
ally as relapses was silenced in agreement with previous
work [17,19] we next undertook detailed quantitative
pathological analysis in the cervical spinal cord, an area
previously demonstrated as consistently and severely
effected during the disease course [11,13,25].
Timing of immunological tolerance influences
immune-reactivity and gliosis
IgG immuno-intensity (Figure 1c-d), used as a surrogate
of general immune-reactivity noting its association with
microglia [26,27] and blood brain permeability [21,28,29],
was examined to further confirm the effectiveness of
auto-immune tolerance to halt immune reactivity.
The temporal increase in IgG immuno-intensity ob-
served in EAE evolution was halted by both early (red
bar, Figure 1d, no significant difference to day 29) and late
(green bar, Figure 1d, no significant difference to day 58)
tolerisation.
CD4 immunopositive reactive T-cells were also quanti-
fied (Figure 2) to verify previous publications detailing
the effectiveness of this tolerisation technique [17,20].
As clearly shown there is a progression of CD4 positive
reactive T–cells at day 29 compared to normal-control
naïve mice (a 9.4 ± 1.6 fold increase Figure 2a, b and f)
that progresses to a 25.7 ± 4.8 fold increase by day 105
(Figure 2a, c and f). Following early-tolerisation (mice
tolerised at day 29 and analysed at day 105), there was
a significant reduction in CD4 positive cells when com-
pared to day 105 non-tolerised EAE mice, with the number
of positive cells being almost identical to day 29 (9.1 ± 2.6
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fold increase compared to normal control mice; Figure 2a,
b, d and f). Late tolerisation had no impact on the number
of increased CD4 positive cells compared to day 105 EAE
tissue (23.3 ± 4.3 fold increase compared to normal control
issue for late whilst it is a 25.7 ± 4.8 fold increase for EAE
at day 105; Figure 2).
IBA1 (ionised calcium binding protein 1) is a calcium
binding protein produced exclusively by microglia and
activated monocytes and is associated with chronic
inflammatory processes. IBA1 positive microglia were
seen to increase as disease progressed. Therefore in
normal control, naïve mice 0.05 ± 0.01% (Figure 3a, g) of
Figure 2 CD4 positive T-cells increase with EAE progression and early tolerisation significantly reduces them. Representative maximum
projected confocal images of CD4 positive cells (shown in white) and cell nuclei (blue) in the dorsal funiculus, with zoomed in areas denoted by
the white dotted-line boxes from normal (a and g N = 3), day 29 (b and h N = 4), day 105-crEAE (c and i N= 3) and following early (d and j N = 4) and
late (e and k N = 5) tolerisation, Scale bars = 100 μm for images a-e and 50 μm for images g-k. These images and the quantification (f) show a
significant, progressive increase in CD4 positive cells penetrating the CNS (black asterisk, P < 0.01, one-way ANOVA), that early tolerisation (red bar,
P < 0.01, one-way ANOVA) significantly reduces compared to day 105-crEAE back to a similar number as at day-29. Late tolerisation (green bar, f) had
no significant effect compared to day 105-crEAE.
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Figure 3 (See legend on next page.)
Hampton et al. Acta Neuropathologica Communications 2013, 1:84 Page 7 of 17
http://www.actaneurocomms.org/content/1/1/84
the dorsal funiculus measured (300 μm from the
surface down) contained IBA1 positive signal. This
increased to 0.08 ± 0.3% at day 29 (not significant,
Figure 3b, g), 0.15 ± 0.2% at day 58 (Figure 3c, g) and
day 105. Following both early and late tolerisation
(mice tolerised at day 29 or 58 and analysed at day 105),
there was no impact on IBA1 density measurements when
compared to day 105 EAE (0.18 ± 0.3 and 0.12 ± 0.3
respectively, Figure 3d, e and g).
In order to examine the influence of early and late tol-
erisation on gliosis the natural history of EAE was first
determined at day 29, 58 and 105 in non-tolerised EAE
and compared to age-matched, normal control naïve mice.
Disease progression was associated with an increased
astrogliosis measured by quantitative GFAP immuno-
histochemistry. There was a significant increase at day 58
(0.54 ± 0.08) and 105 (0.69 ± 0.07) compared to day 29
(0.20 ± 0.01) and naive mice (0.26 ± 0.05) (Figure 4;
p < 0.01), which is in agreement with previous results
[13]. Following early-tolerisation (mice tolerised at
day 29 and analysed at day 105), there was a signifi-
cant reduction in GFAP positive cells (0.44 ± 0.07,
red bar and line Figure 4g and e; p < 0.01) when compared
to day 105 non-tolerised EAE mice (0.69 ± 0.07). However,
early tolerised animals (analysed at day 105) still have
significantly elevated numbers of GFAP positive astrocytes
compared to EAE mice analysed at day 29 (red bar
Figure 4g; p < 0.01), despite the complete absence of
further clinical relapses (red line, Figure 1b). However
GFAP quantification of late tolerised mice showed no
difference when compared to non-tolerised EAE mice
analysed at day 58 or 105 (green bar, Figure 4g).
Early immune suppression does not prevent
neurodegeneration
To study the influence of tolerisation on neuroaxonal
status quantitative analysis of two classes of spinal cord
neurons and axons was undertaken. ChAT positive
motor neurone quantification within lamina IX of the
ventral horn in the cervical cord showed progressive loss
of neurones as EAE developed, at all three time points
studied, that is day 29, day 58 and day 105, when these
timepoints are compared to normal, control naïve mice.
Thus at day 29 there were 75.9 ± 8.5% ChAT+ neu-
rons compared to control naïve mice. This progresses
to 49.0 ± 5.5% at day 58 and 42.8 ± 4.8% survival at
day 105 (Figure 5a-g).
Comparable progressive neuronal loss was also evident
in the lateral spinal nucleus (LSN) a longitudinal sensory
nucleus found in the dorsolateral white matter involved
in homeostatic and noiciceptive signalling [24]. Spe-
cifically at day 29–57.9 ± 8.6% NeuN+ neurones were
present compared to normal, control naive mice with
38.8 ± 8.9% NeuN+ at day 58 and 22.9 ± 5.6% by day 105
(Figure 5h-n). These findings are consistent with earlier
studies that showed early loss of spinal cord neurones in
MS and an alternative form of EAE [30,31].
Having demonstrated progressive neuronal loss in
EAE the effect of tolerisation was next studied. Quantifi-
cation of ChAT+ positive neurones in the ventral horn
(58.7 ± 6.6% survival in early tolerisation analysed at
105 days compared to 42.8 ± 4.8% survival in non-
tolerised EAE mice analysed at the same timepoint of
105 days, Figure 5a-g, red bar and lines; p < 0.01)
revealed a beneficial effect of early tolerisation. This
beneficial effect was also present in the LSN where an
lack of a decrease in NeuN positive neurones was also
observed (38.4 ± 8.7% surviving following early tole-
risation versus 22.9 ± 5.6% in non-tolerised EAE mice
analysed at the same timepoint of 105 days; Figure 5h-n,
red bar and lines, p < 0.01).
However, both ChAT and NeuN analysis of early
tolerisation revealed a significant ongoing neuronal loss
despite the absence of further clinical events following
early tolerisation (red line Figure 1b). Therefore counts
of both ChAT and NeuN positive neuronal populations
show that even in the absence of further clinical relapses
in the intervening time (from day 29 to 105) there has
been a significant, progressive loss of neurones (Figure 5,
red bars and lines; p < 0.01). For ChAT this was a loss of
over 15% (75.9 ± 8.5% positive neurones at day 29 com-
pared to 58.7 ± 6.6% surviving in early tolerised mice). A
similar loss of around 19% was found for NeuN positive
neurones (57.9 ± 8.6% at day 29 dropping to 38.4 ± 8.7%
surviving at 105 days following early tolerisation).
Early immune suppression does not prevent
axonal degeneration
In order to address whether tolerisation also influenced
axonal status we undertook multiple methods of analysis
(See figure on previous page.)
Figure 3 IBA1 positive, chronically activated microglia increase with EAE progression however both early and late tolerisation have no
effect on this increase. Representative maximum projected confocal images of IBA1 (white) positive microglial cells and bis-benzamide (blue) in
the dorsal funiculus in normal (a, N = 4), day 29 (b, N = 5), day 58 (c, N = 5), day 105-crEAE (d, N = 7) and following early (e, N = 5) and late
(f, N = 7) tolerisation. Quantification (g) shows a progressive increase in IBA1 positive cells in the dorsal funiculus that is significantly elevated at
day 58 and 105-crEAE (black asterisk, P < 0.01, one-way ANOVA). Neither early (red bar) nor late tolerisation (green bar) had any significant effect
on this increase in IBA1 positive microglia. Scale bar = 50 μm for all images.
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as we did for neuronal status. CGRP quantification
within the dorsal horn (to identify primary afferent
processes [13,24]) and semithin analysis within another
region of the cervical spinal cord, the dorsal funiculus,
predominantly comprised of ascending primary sensory
afferents [13,24]. Both methods of analysis showed
progressive and significant axonal loss as disease pro-
gressed, as also observed for neuronal loss. For CGRP
positive processes no loss was observed at day 29 EAE
mice (0.57 ± 0.05) compared to normal, control naive
mice (0.56 ± 0.1). However by day 58 of EAE progression
CGRP had significantly decreased to 0.41 ± 0.05 and
(See figure on previous page.)
Figure 4 GFAP reactive gliosis increases with EAE progression. Gliosis is significantly reduced by early tolerisation but still progresses even in
the absence of further clinical relapses. Representative images of GFAP positive reactive astrocytes in the dorsal funiculus in normal (a, N = 4) day
29 (b, N = 5), day 58 (c, N = 5), day 105-crEAE (d, N = 7), and following early (e, N = 4) and late (f, N = 7) tolerisation. Quantification (g) shows a
progressive increase in GFAP reactivity, (black asterisk) that early tolerisation (red bar and asterisk in g) significantly reduces compared to day
105-crEAE. However it remains significantly elevated compared to day 29, showing increased astrocytosis even in the absence of the primary
relapse-remitting driven immune response. Late tolerisation (green bar in g) had no significant effect on GFAP reactivity compared to day 58 or
105-crEAE timepoints (asterisk = P <0.01, one-way ANOVA). Scale bar = 200 μm for all images.
Figure 5 Neuronal loss following EAE progression is reduced following early tolerisation but still persists despite the absence of
further clinical relapses. ChAT positive motor neurones in the ventral horn in normal, naïve control mice (a, N = 3), as EAE progresses at day 29
(b, N = 5), day 58 (c, N = 5) and day 105-crEAE (d, N = 7), following early (e, N = 4) and late (f, N = 7) tolerisation. Quantification of ChAT (g)
positive cell counts showing early, progressive neuronal loss. Following early tolerisation neuronal loss was decreased compared to day 105-crEAE
(red bar and lines g). However this loss was greater then observed at day 29 (ChAT - red bar and lines g) showing that neuronal loss is amelio-
rated however still progresses even in the absence of further clinical relapses. Late tolerisation had no effect on this neuronal loss (f and green
bar g). NeuN positive neurones in the lateral spinal nucleus (LSN), as demarcated by the white dotted lines, again in normal, naïve control mice
(h, n = 3), as EAE progresses at day 29 (I, n = 5), day 58 (j, n = 5), day 105-crEAE (k, n = 4), following early (l, n = 4) and late (m, n = 5) tolerisation.
Quantification of NeuN (n) showing early, progressive neuronal loss. Following early tolerisation neuronal loss was decreased compared to day
105-crEAE (red bar and lines n). However this loss was greater then observed at day 29 (red bar and lines n) showing that neuronal loss is
ameliorated however still progresses even in the absence of further clinical relapses. Late tolerisation had no effect on this neuronal loss
(NeuN-m and green bar n). Scale bar = 100 μm for all images, significance for data, P < 0.01, one-way ANOVA.
Hampton et al. Acta Neuropathologica Communications 2013, 1:84 Page 10 of 17
http://www.actaneurocomms.org/content/1/1/84
then progressed further to 0.21 ± 0.03 by day 105
(Figure 6a-f, quantified in g). Counts of semi-thin resin
sections of spinal cord, showed that at every time point
studied in the non-tolerised EAE mice compared to con-
trol naive mice there was progressive loss. Therefore at
day 29 a loss of 11.7% ± 5.4, 58.6% ± 2.5 loss at day 58
and 76.2% ± 1.4 loss at day 105 (Figure 7a-f and linked
zoomed areas g-l and m-r, quantified in s; p < 0.01).
Further analysis of axonal numbers by both CGRP and
semithin methods again revealed a protective effect with
early tolerisation. CGRP density measured in early
tolerised mice (i.e. mice tolerised at day 29 and analysed
at day 105) showed 0.32 ± 0.05 compared to a loss of
0.21 ± 0.03 in day 105 non-tolerised EAE mice (red bar
and line Figure 6g). Semithin analysis showed a 28% ±
4.4 loss in early tolerised mice analysed at day 105
compared to 76.2% ± 1.4 loss in day 105 non-tolerised
EAE mice (red bar and line Figure 7s). However
although both CGRP and semithin analysis showed an
axonal protective effect there was still on-going signifi-
cant progressive axonal loss when comparing early
tolerised mice analysed at day 105 to day 29 (Figures 6g
and 7s red bar, lines and asterisks), the same effect as
was observed for ChAT and NeuN positive neurones.
Total spinal cord area measurements excluded tissue
oedema and/or atrophy accounting for the observed
changes in axonal counts (Additional file 1: Figure S1).
Interestingly late tolerisation had no axonal-protective
effect in CGRP analysis in the dorsal horn (Figure 6d, f
and green bar in g) but did confer an axonal-protective
effect although more modest than early tolerisation at
60.8 ± 2.4 compared to 76.2% ± 1.4 for crEAE (p < 0.01,
green bar and line, Figure 7) for semithin analysis in the
dorsal funiculus.
Our results therefore show subtle differences between
the effect of early tolerisation on different neuronal and
axonal areas as well as differences between early and late
tolerisation and this in part is because different tracts
and/or neuronal areas are impacted at different times
during disease progression (Additional file 2: Figure S2).
For example CGRP positive axons in the dorsal horn
show no loss at day 29, but a loss at 58 days of EAE
progression, with progressive axonal loss even following
early tolerisation (Additional file 2: Figure S2b).
Inhibition of relapsing autoimmunity by immune
tolerance is associated with increased remyelination
Having established that early tolerisation reduces but
does not stop neuroaxonal loss, the influence of tolerisa-
tion on myelination status (demyelinated, remyelinated
or normally myelinated) of surviving axons was inves-
tigated. Quantitative semithin analysis of spinal cord
sections revealed a significant reduction in normally
myelinated axons in non-tolerised EAE from 77.0 ± 6.9%
at day 29 to only 6.7 ± 3.6% by day 105 (Figure 7a,
balong with linked magnified panels in g, m and yellow
segments in t). Early tolerisation, analysed at day 105,
resulted in a significant reduction in this loss of normally
myelinated axons (39.4 ± 7.3% compared to 6.7 ± 3.6% of
non tolerised EAE mice at day 105, yellow segments in
Figure 7t; p < 0.01). However, again this proportion was
significantly less than that at day 29 in non-tolerised EAE
alone (39.4 ± 7.3% compared to 77.0 ± 6.9%, Figure 7t;
p < 0.01). Late tolerisation had no significant effects
on the proportion of normally myelinated surviving
axons (13.1 ± 4.9%, yellow segments in Figure 7t when
compared to either day 58 or 105 non-tolerised crEAE,
Figure 7t).
Noting the comparatively small percentage of surviv-
ing, demyelinated axons in all study groups (pink bars in
Figure 7t) we next determined whether neuroprotection
associated with tolerisation was related to remyelination
status. Quantification of remyelinated axons, identified
morphologically as axons with thin blue encircling layer
of myelin compared to normal thick myelin, showed that
early tolerisation significantly increased remyelination
compared to both day 29 and 105 in non-tolerised EAE
(28.4 ± 4.1% versus 7.6 ± 2.9% at day 29 and 8.5 ± 2.9% at
day 105; blue segments in Figure 7t; p < 0.01). Late
tolerisation also showed a more modest, but nonethe-
less, significant promotion of remyelination compared to
day 58 non-tolerised EAE (17.3 ± 3.7%, versus 11.5 ±
2.0% at day 58; p < 0.01; blue segments in Figure 4t).
Taken together, these findings reveal a progressive
neurodegeneration despite suppression of the CD4
driven, myelin targeting immune responses that is also
associated with enhanced remyelination and that chron-
ically activated microglia may play a key role in this
neurodegenerative process.
Discussion
This study sought to understand the pathological con-
sequences of tolerisation in an experimental model of
chronic multiple sclerosis. We show that elimination of
clinical relapses by immunological tolerance, even after
the first clinical event, although partially neuroprotective
is, of itself, insufficient to prevent ongoing and signifi-
cant neurodegeneration (1,26,36). Furthermore we show
that following tolerisation (both early and late, although
to a lesser extent in late tolerisation) there is a significant
increase in remyelination. These findings are consistent
with an uncoupling, in part at least, of autoimmune-
driven inflammation and neurodegeneration in evolving
disease. This has clear similarities with progressive mul-
tiple sclerosis, which also does not appear to respond to
peripheral immunosuppression [1,5,17,19,32]. Whilst im-
munological tolerance induction inhibits peripheral T cell
function and controls relapsing disease and accumulation
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Figure 6 CGRP positive axonal loss within the dorsal horn develops with EAE, is reduced following early tolerisation but still
progresses even in the absence of further clinical relapses. CGRP positive primary afferents in the dorsal horn in normal, naïve control mice
(a, N = 4), as EAE progresses at day 29 (b, N = 5), day 58 (c, N = 5) and day 105-crEAE (d, N = 6), as well as following early (e, N = 4) and late
(f, N = 7) tolerisation. Quantification (g) shows a progressive loss (black asterisk) over disease course that is reduced following early tolerisation,
however still persists when compared to day 29 (g - red bar, lines and asterisk). Late tolerisation had no significant impact on progression of
CGRP loss (g, green bar). Scale bar = 100 μm for all images, significance for all data, P < 0.01, one-way ANOVA.
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of T cells within the CNS [17,18], as tolerance induc-
tion is dependent on the presence of regenerating T
cells, it is not possible to totally exclude a role of T
cells in the development of progressive neurodegenera-
tion, especially through a central action involving glial
inflammation [7]. Although early tolerisation resulted in
minimal clinical deficit it is important to recognise that
the clinical behavioural scale used for EAE is ordinal
and insensitive to subtle but significant clinical deficits.
Consequently although valuable it may not directly
translate to patient disability and emphasises the im-
portance of histological quantification of actual neuroax-
onal damage.
Our study extends earlier reports that Biozzi ABH
EAE faithfully reproduces many key temporal, clinical
and pathological features of MS [12,13,19]. Specifically
the temporal evolution of early clinical relapses followed
by progression, independent of relapses, associated with
accumulating demyelination, remyelination, gliosis and
neuroaxonal degeneration supports its use to model RR-
SPMS. The effectiveness of tolerisation to eliminate
further clinical relapses has previously been shown and
characterised [17-19] and we further verify the effective-
ness of this technique to silence the CD4 positive, T-cell
driven EAE in the Biozzi ABH mouse. Notwithstanding
our results and these earlier studies of tolerisation
[17-19] we now provide additional evidence that aboli-
tion of clinical relapses following tolerisation is associ-
ated with reduced immune responses measured by
reduction in IgG immunoreactivity noting that IgG im-
munoreactivity is used as a measure of microglia [18,26]
and also blood brain barrier disruption/permeability
[21,28,29]. Taken together, the ability to reliably eliminate
clinical relapses along with pathological surrogates of
inflammation using an established immune based tolerisa-
tion strategy accurately mirrors current clinical scenarios
where second-generation DMTs are able to prevent fur-
ther clinical and radiological measures of inflammation
[32,33]. This allowed the question of whether timing of
“immune-treatment” alters clinical and pathological course
of EAE to be addressed. Resolving this question in
humans is self-evidently difficult in terms of pathological
assessment despite advances in MR based imaging and
definitive clinical evaluation requires many years of follow
up given the temporal evolution of disease progression.
Two major observations are evident following early
and late tolerisation. Firstly effective suppression of
clinical and immunological measures of inflammation
even after the first clinical event, although beneficial and
significantly more effective than late tolerisation in
respect to neuroaxonal status, does not prevent progres-
sive neuroaxonal loss. We determined this across not
only multiple regions of the spinal cord but also using
multiple techniques that reveal a consistent pattern
across not only ascending tracts and nuclei (the dorsal
funiculus and lateral spinal nucleus) but also primary
afferent processes within the dorsal horn (CGRP) and
ventral motor areas (ChAT positive neurones). This sug-
gests that neurodegeneration can evolve independently
of active autoimmunity. Further to this observation we
have data that shows that chronically activated CNS
microglia (IBA1 positive) may well be involved in this
process since neither early nor late tolerisation had any
impact on the development of significant increases in
IBA1 positive cells (Figure 3) measured after 105 days of
progression. Importantly total area measurements of the
spinal cord exclude tissue oedema and/or atrophy
accounting for the observed changes in axonal counts.
Secondly remyelination appears to be enhanced fol-
lowing tolerisation, with earlier intervention significantly
more effective than later tolerisation. This finding is in
contrast to other studies that have shown inflammation
promoting remyelination [8,10]. This may reflect differ-
ences in models; specifically, use of non-myelin driven
disease and focal injuries compared to, as in this study, a
systemic myelin mediated injury model associated with
a progressive neurodegenerative component. Although
these experiments were not designed to elucidate the
(See figure on previous page.)
Figure 7 Axonal loss, demyelination and remyelination progresses following EAE induction. Following tolerisation axonal loss is reduced
however still progresses despite the absence of further clinical relapses. Semithin sections from normal, naïve control mice (a, g and m; N = 5), as
EAE progresses at day 29 (b, h and n; N = 5), day 58 (c, i and o; N = 5) and 105 days (d, j and p; N = 8), following early (e, k and q; N = 5) and
late (f, l and r; N = 5) tolerisation. Panels g-l and m-r are higher magnification images from the red and green boxes respectively in panels a-f.
Quantification shows progression of axonal loss (s), with total axonal survival decreasing as EAE progresses, black asterisks (s). Early tolerisation
reverses this trend with significant axonal survival (red bar, s) and late tolerisation also has a small but significant effect on axonal survival
compared to day 105-crEAE (green bar, s). However, following early tolerisation there is still a significant decrease in axonal survival observed
when comparing day 29 to early tolerised mice (s, red bar and asterisks). The majority of those axons surviving at day 29 were normally
myelinated (i.e. unaffected) as shown in panel t, yellow segment. Following early tolerisation a significant increase in these remaining normally
myelinated axons compared to day 105-crEAE was observed, but a significant decrease compared to day 29 (t, yellow segments) showing a
progression on axonal degeneration, even in the absence of the primary immune response. Furthermore remyelination (examples shown by the
black arrows in e and f) is significantly increased in early, and to a lesser extent late, tolerised mice by the blue segments (t). Scale bars = 25 μm
(a-f) and 5 μm (g-r), significance for data, P < 0.01, one-way ANOVA.
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role of remyelination in neuroprotection our findings
are consistent with the idea of remyelination being
neuroprotective [34-36]. However although we observe
that following early tolerisation there is an increase in
remyelination there is significant, ongoing axonal and
neuronal degeneration as well as an increase in chronically
activated microglia. There are other studies that have
shown this phenomenon of axonal loss despite extensive
remyelination [15]. This is also important since in-
creases in reactive microglia were also noted. So
although we cannot definitively say that it is this
increase in chronically-activated microglia driving this
progressive axonal loss or merely being a conse-
quence of it, there is an increasing amount of litera-
ture reporting microglial-induced neurodegeneration
in several different models.
A final observation regarding neuronal loss is that
comparing early to late tolerisation a small (but still
significant) difference was observed in ChAT positive
motor neurones (Figure 5g) but not NeuN positive
neurones in the LSN (Figure 5n), whilst there are clear
behavioural differences between early and late tolerised
animals as shown in the EAE clinical scoring. This
re-iterates the fact that we analysed multiple areas of
the spinal cord and it must be remembered that the
EAE scoring system is a motor behavioural task and
motor neurones do show a significant difference as
well whilst the NeuN positive neurones are in an as-
cending sensory pathway (the LSN is associated with
homeostatic and nociceptive signalling) that is not
related to this motor EAE behavioural scoring system.
Interestingly the GFAP and semithin analysis were also
performed in an ascending sensory area, the dorsal funi-
culus and also show a significant difference between early
and late tolerisation like the ChAT positive motor
neurones. However it should be noted that this tract is
not exclusively sensory, although it is predominantly com-
prised of ascending primary afferent axons that are
integral to correct motor function. This merely further
highlights the complexity of this model showing the need
to undertake multiple methods of analysis in an effort to
better understand it.
It should also be noted that different axonal tracts and
neuronal nuclei are impacted by EAE at different times
(Additional file 2: Figure S2). In EAE lymphocytic lesions
are concentrated in the white matter however it is clear
that there are both white and grey matter influences as
we have shown. The main point is that we have taken a
constant region (C5) and shown clearly that different
nerve tracts are affected at different times during the
relapsing course of EAE in Biozzi mice.
Although our studies are undertaken in an adult
mouse it would be of interest to examine an older group
and extend evaluation beyond 105 days noting that
human disease progression is age-dependent [3,4]. Previ-
ous studies have indicated that very late tolerisation after
two to three relapses does not stop neurological pro-
gressive disease [17,19]. These current experiments were
initiated in mice aged 2–4 months and maintained for
another 3 months which is broadly comparable to a
human aged between 20–35 years (based from JaxLabs;
webpage address - http://research.jax.org/faculty/harrison/
ger1vLifespan1.html). It is therefore likely that our study
underestimates long-term equivalent neurodegeneration
in a clinically relevant aged human cohort. Furthermore
the remyelination that does occur is known to be not as
thick as normal myelin [14] and it is also known that age
significantly alters not only the remyelination potential
but also the injury response to the initial demyelinating
episode [37-39]. Therefore by investigating this phene-
moenom in aged Biozzi-ABH mice we might be able to
elucidate some reasons for the progression of MS in
people.
Conclusions
In summary, these findings highlight that although timing
of anti-inflammatory immune based therapies is critical,
even intervention after the first clinical event is unlikely to
prevent all long-term neurodegeneration. The clinical
implications of these findings are that prevention of
progression and long-term clinical disability is likely to
require both early and combinatorial immune-suppressant
and CNS neuroprotective interventions. Furthermore any
neuroprotective intervention may well need to address
chronically activated microglia that may well be key to this
‘slow-burn’ neurodegeneration that is independent of
immune-driven relapses.
Additional files
Additional file 1: Figure S1. Representative semithin image sections
and graph showing that total area measurements of the spinal cord at all
time points are not significantly different therefore tissue oedema and/or
atrophy cannot account for the observed changes in axonal counts.
Representative semithin images from normal (a, N = 3), day 29 (b, N = 4),
day 58 (c; N= ) and day 105-crEAE (d, N = 3). Quantification (e) shows no
significant differences between any timepoint nor following early or late
tolerisation. Scale bar = 1000 μm for all images.
Additional file 2: Figure S2. Graphs showing differences between
percentage loss of axons and neurones as disease progresses and
following tolerisation. Graphs showing varied axonal (a and b) and
neuronal (c and d) loss using quantified semithin axonal counts in the
dorsal funiculus(a), CGRP positive terminals in the dorsal horn (b), ChAT
positive neurones in the ventral motor horn (c) and NeuN positive
neurones in the lateral spinal nucleus (d). Normal EAE disease course is
shown at day 29 (N = 5), 58 (N = 5) and 105 (N = 6) (black bars) with early
tolerisation (red bar, N = 5) and late tolerisation (green bar, N = 6) being
compared to the timepoint when tolerisation occurred and any nerve
loss highlighted is significant (P < 0.01, one-way ANOVA).
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